To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituximab-augmented donor lymphocyte infusions) was guided by minimal residual disease (MRD) monitoring and commenced at a median of 91 (22-273) days after alloHCT, resulting in a probability of being event free and MRD-negative 1 year after transplant of 57% (84% in those encountering chronic GvHD). Patients who were event free and MRD-negative at the 12-month landmark had a 4-year PFS of 77% and largely remained durably MRD-negative if MRD clearance had occurred subsequent to immune modulation. Three-year overall survival, PFS, relapse incidence and non-relapse mortality of all 77 patients were 69, 57, 26 and 24%, respectively. Survival was not affected by EBMT risk category but by active disease at alloHCT, which could not be overcome by intensification of conditioning. Twenty-three patients who experienced relapse post alloHCT had a survival of 56% at 2 years after CLL recurrence. In conclusion, MRD-guided immune modulation after alloHCT for high-risk CLL can provide durable MRD clearance in more than half of the patients.
INTRODUCTION
Despite the recent advent of highly effective molecular therapy, [1] [2] [3] the only curative therapy option for poor-risk CLL is offered by allogeneic hematopoietic stem cell transplantation (alloHCT), which can confer long-term PFS in up to 50% of patients. [4] [5] [6] [7] [8] [9] [10] Disease control after alloHCT seems to mainly depend on GvL activity, as suggested by the opposed effects of chronic GvHD (cGvHD) and T-cell depletion on disease control, [11] [12] [13] [14] the efficacy of donor lymphocyte infusions (DLI) 10 and, most importantly, the delayed kinetics of minimal residual disease (MRD) disappearance after alloHCT. 12, 15, 16 Patients who manage to clear MRD by defined landmarks at 6-12 months post alloHCT have a significantly lower relapse risk than those who fail to become MRD-negative by these time points. 10, 12, 15 However, it is unclear if MRD-guided immune intervention increases the probability of achieving MRD clearance at prognostic landmarks after alloHCT. Specifically, little is known about the inter-relationship between post-transplant immune modulation, cGvHD and MRD kinetics as surrogate for GvL activity, and also the impact of other factors, such as conditioning intensity, on the MRD course. Finally, the efficacy of secondary immune-modulating interventions and the overall outcome in case of MRD or clinical disease recurrence after alloHCT is poorly characterized. To address these questions, a retrospective analysis was performed that recorded timing and dynamics of immune modulation, cGvHD, MRD and clinical outcome of a large series of patients allografted for poor-risk CLL in a single institution.
PATIENTS AND METHODS

Study design and patient eligibility
Eligible for this retrospective single-center analysis were all consecutive patients who were allografted for CLL at our institution between January 2005 and April 2013. Transplant indication was defined by the EBMT criteria, 17 or a history of Richter's transformation. For assigning individual patients to an EBMT risk category, a hierarchical procedure was followed by giving TP53 abnormalities priority over fludarabine refractoriness, and fludarabine refractoriness priority over early relapse after intensive therapy. 18 Primary end point was to determine the proportion of patients who achieved MRD negativity in the absence of clinical events (relapse, graft failure, NRM) at the 12-month landmark.
Clinical data were collected by chart review and stored in a study-specific database. Clinical follow-up and MRD sampling was performed in analogy to the CLL3X trial. 19 Quantitative MRD assessment was done by highresolution four-color flow cytometry (MRD flow) based on an internationally standardized three-tube assay described by the ERIC consortium. 20 A sensitivity of 10 −4 was achieved by systematically acquiring at least 200 000 nucleated cells per tube. MRD positivity required the identification of clusters of at least 20 CLL cells in at least two out of the three MRD tubes, while MRD negativity was defined as failure to reach this criterion. 21, 22 cyclophosphamide conditioning for patients being refractory or having a mismatched donor, following the algorithm of the CLL3X study. 15 As of March 2009, fludarabine/busulfan/cyclophosphamide was replaced by fludarabine/treosulfan (FT, fludarabine 30 mg/m 2 per day from day − 6 through − 2, and treosulfan 10-14 g/m 2 per day from day − 6 through day − 4), 23 and as of June 2012 FT was used also for sensitive patients. As of July 2011, refractory patients were conditioned with fractionated TBI (total dose 6-8 Gy in 3-4 doses) and fludarabine (TBI8Flu). 24 In cases of unrelated donors, ATG Neovii (10 mg/kg per day) was added from day − 3 through day − 1. For the purposes of this study, fludarabine/busulfan/cyclophosphamide and TBI8Flu were considered as myeloablative conditioning, fludarabine/cyclophosphamide as non-myeloablative, and FT as reduced intensity conditioning according to the Working definitions. 25 Supportive therapy included anti-infectious prophylaxis with cotrimoxazole, acyclovir, fluconazol and ciprofloxacin; ursodeoxycholic acid for prophylaxis of hepatic complications; and regular screening for EBV or CMV reactivation. 26, 27 From 2010 onwards, all patients were put on pravastatin during calcineurin-inhbitor (CNI) administration for preventing vascular complications associated with these drugs. GvHD prophylaxis consisted of a CNI (cyclosporin A or tacrolimus) along with short-course methotrexate or mycophenolate mofetil.
MRD-driven immune modulation
Although not following a prospectively defined algorithm, CNI tapering was attempted in the absence of GvHD from day +70 onwards in patients with MRD persistence and/or refractory disease status at transplant, and from day +100 onwards in patients meeting none of these criteria. Patients who showed persisting or increasing MRD levels after complete withdrawal of CNI received pre-emptively combined humoral and cellular immunotherapy with rituximab and DLI in escalating doses in 8-12 week intervals as pioneered by investigators from the MD Anderson Cancer Center. 8 Rituximab with escalating DLI was also the first-line salvage treatment for clinical disease recurrence after alloHCT. DLI starting dose was 1-5 × 10 6 /kg CD3+ cells depending on donor source and DLI indication (pre-emptive vs therapeutic). 
Statistical analysis
Fisher's exact test was used to compare categorical factors between groups of patients. For continuous variables the Mann-Whitney test was applied. Kaplan-Meier product-limit estimates were used for calculating survival. Events for overall survival (OS) were defined as death from any cause. Events for PFS were defined as relapse, progression or death from any cause, whatever came first. Survival curves were compared using logrank tests. Multivariate analyses of OS and PFS were performed using Cox regression modeling. Incidences of relapse and NRM were calculated by cumulative incidence curves to account for competing risks and compared by the Gray test. Multivariate analysis of relapse incidence and NRM were performed using Fine and Gray regression models. Calculations were done using GraphPad Prism software (release 5.0; San Diego, CA, USA), and the statistical computing language R (version 2.15.2: R Foundation for Statistical Computing, Vienna, Austria). Significance levels were set at 0.05. Data were analyzed as of 31 March 2015.
RESULTS
Patients
Between November 2005 and April 2013, 77 patients underwent alloHCT for CLL. Twelve of these were treated within the CLL3X protocol 15 and updated for the purposes of this study. Transplant indication (hierarchical) was Richter's transformation in four patients, 17p-/TP53mut (salvage situation) in 18 patients, 17p-/ TP53mut (first remission) in 10 patients, fludarabine resistance without 17p-/TP53mut in 29 patients, and early relapse (relapse within 7-24 months after intensive pre-treatment in the absence of 17p-/TP53mut) in 16 patients. Conditioning was considered as non-myeloablative/reduced intensity conditioning in 57 patients and as myeloablative conditioning in 20 patients. Patient characteristics are detailed in Table 1. MRD response patterns, immune-modulatory maneuvers and GvHD Regarding MRD response patterns, 10, 19 17 out of 77 patients were not informative because of early death (within 4 months, n = 8), early relapse (within 4 months, n = 5), non-engraftment (n = 3) or missing samples during the first 9 months after transplant (n = 1), leaving 60 patients evaluable for MRD response. Figure 1 summarizes the assignment of these patients to defined MRD response patterns including the specific chronological and quantitative relations between immune interventions, MRD response, chronic GvHD and outcome.
In these 60 patients, the cumulative incidence of overall and extensive chronic GvHD at 12 months after alloHCT was 61 and 42%, respectively. Since in some patients chronic GvHD was only transient, the prevalence of overall chronic GvHD at the 12-month landmark was less (43%), requiring systemic immunosuppressive treatment in 20 (33%) out of the 60 patients (Supplementary Figure 1) . The 38 patients who encountered chronic GvHD within the first year post transplant had a higher probability of being alive and MRD-negative at the 12-month landmark than the 22 patients without chronic GvHD (84 vs 64%, P = 0.054). Grades 2-4 (3-4) acute GvHD occurred in 14 (9) patients (18%/12%).
Immunosuppression tapering was commenced at a median of 91 (22-273) days after HCT in those 67 patients where it was attempted. Earlier immunosuppression reduction was recorded for patients who had MRD persistence after transplant (compared with those who were MRD-negative immediately after transplant, 88 vs 97 days), and for patients with refractory disease at alloHCT (compared with those with sensitive disease, 67 vs 92 days), but none of these differences were statistically significant. Early immunosuppression tapering (before day +90) was not associated with increased NRM (Supplementary Figure 2) .
Outcome by MRD status at +12 months Out of the 60 patients with GvL response pattern available, 9 died or relapsed before the 12-month landmark. Of the remaining 51 patients being alive and relapse free at this timepoint, 43 patients were MRD-negative and 8 patients were MRD-positive. Overall, the probability of being event free (event: death, relapse, nonengraftment) and MRD-negative at the 12-month landmark was 57% (44 out of 77 including the patient who was MRD-negative but could not be assigned to a GvL response pattern).
MRD negativity 1 year after alloHCT was found to have a highly significant impact on relapse risk (hazard ratio (HR) 0.045; 95% confidence interval (95% CI) 0.01-0.15; P = 0.008; Figure 2a ). Clinical relapse was preceded by MRD recurrence in the five patients who relapsed in the MRD-negative group. One additional patient showed MRD recurrence without clinical relapse yet, translating into an incidence of MRD relapse of 13% (95% CI 0-54%; Figure 2b ) at 4 years after the 12-month landmark. Of note, just one out of the six MRD reconversion events occurred in those patients who had become MRD-negative only after immune intervention (GvL response patterns #2/#3; Figure 2 ). In the MRDnegative and MRD-positive patients, respectively, PFS was 77% (95% CI 57-88%) and 33% (95% CI 6-66%) (P = 0.019), and OS 90% (95% CI 74-96%) and 50% (95% CI 15-77%) (P = 0.03) 4 years after the 12-month landmark.
Overall outcome and prognostic factors With a median follow-up of survivors of 44 (21-111) months, 23 patients died. Leading cause of death was CLL progression in 9 patients; sepsis/early toxicity during the aplastic phase in three patients; acute GvHD in three patients; chronic GvHD in four patients; secondary malignancy in two patients; and late infection and immune thrombocytopenia each in one patient. Three year OS, PFS, relapse (REL) and NRM were 70, 56, 28 and 22%, Disease eradication after alloHCT in CLL M Hahn et al respectively (Figure 3) . By univariate analysis, sensitive disease status at alloHCT was a significant predictor for favorable OS (HR 0.2, 95%CI 0.07-0.6; P = 0.0042), PFS (HR 0.32, 95%CI 0.13-0.78; P = 0.013) and NRM (HR 0.12, 95%CI 0.03-0.471; P = 0.0023), but not REL. In contrast, myeloablative conditioning was associated with adverse OS (HR 2.94, 95%CI 1.34-7.61 P = 0.027), PFS (HR 2.19, 95%CI 0.99-4.79; P = 0.051) and NRM (HR 5.5, 95%CI 1.7-18.3; P = 0.0053), but not REL (Supplementary Figures 3, 4) . Age, gender, number of pre-treatment lines, donor source and EBMT risk category had no significant impact on any clinical end point (Supplementary Table) . Specifically, patients with 17p-who underwent alloHCT in first remission did not show significant outcome differences for any survival end point if compared with other HR-CLL (Supplementary Figures 5, 6 ). In multivariate analyses considering disease status, conditioning, EBMT risk category (17p-/TP53mut vs other), and donor source, only the favorable impact of sensitive disease at alloHSCT on PFS (HR 0.44, 95%CI 0.2-0.96; P = 0.039) and OS retained significance (HR 0.33, 95%CI 0.13-0.82; P = 0.017), whereas all other variables were NS for any end point. Neither disease status at alloHCT, conditioning intensity, nor donor source had a significant impact on the probability of being MRD-negative (and event free) at the 12-month landmark.
Treatment and outcome of CLL relapse after alloHCT Altogether 23 patients experienced clinical relapse or progression after a median time interval of 11 (3-83) months after alloHCT. The primary rescue strategy was DLI+rituximab (R), which was administered to 13 out of 23 patients. (DLI could not be given to 7 out of 23 patients because of preceding graft failure (2) Disease (1)). Three patients who relapsed recently are currently under ibrutinib with the intention of administering DLI upon maximum response. Of the relapsed 13 patients who received DLI, five had been given DLI already before clinical relapse pre-emptively upon MRD persistence ( Table 2) . The other eight patients could not be treated pre-emptively because of CLL recurrence before withdrawal of systemic immunosuppression (6), donor pregnancy (1) and simultaneous occurrence of MRD and clinical relapse (1) . Although all 13 patients who received DLI+R showed at least some temporary stabilization, a sustained MRD-negative CR was observed in only two patients (15%). Chronic GvHD subsequent to DLI developed in 5 out of 13 patients (38%), including one of the two long-term responders. As secondary salvage regimen, lenalidomide+R was given to 6 out of the 11 DLI failures, resulting in CLL regression in two of them including one durable MRDnegative CR. Three patients received chemoimmunotherapy with limited success, and the most recent two relapses were treated with ibrutinib (Figure 4) . With a median observation time after relapse of 19 (2-63) months, 13 out of 23 patients are alive according to a 2-year survival probability of 56% ( Figure 5 ). None of the four patients who had relapsed with transformed CLL survived. No other prognostic factor for OS after relapse could be identified.
DISCUSSION
It may be argued that there is no longer need for alloHCT in highrisk CLL because of the advent of a variety of effective drugs targeting signaling pathways. 28 However, although impressively effective even in otherwise refractory disease, it seems that both ibrutinib and idelalisib as the best developed compounds of this type cannot provide durable disease control in relapsed high-risk disease. 2, 29 Thus, although the novel treatment options undoubtedly will alter transplant indications, it appears that alloHCT will continue to have a role in CLL. 30 In this context it needs to be emphasized that our study for the first time shows that EBMT risk category does not affect alloHCT outcome, that is, patients with relapsed 17p-CLL had a prognosis similar to the other risk categories.
Taking all 77 patients undergoing alloHCT as the denominator (representing the largest sample analyzed for this question to date), the probability of being MRD-negative and event-free 1 year after transplant was 58%. MRD negativity at this landmark indicated a relapse risk o 20% until the end of follow-up. This finding is in keeping with landmark analyses from previous studies that consistently showed virtual absence of relapse in patients who were MRD-negative 6-12 months after alloHCT. 9, 10, 12, 31 Our observation that only a few patients of the MRD-negative subset experienced subsequent MRD recurrence and none of them did so beyond 4 years post transplant confirms that disease control might be durable in a substantial proportion of these patients. An unprecedented finding was that MRD reconversions after being negative at the 12-month landmark were largely restricted to those patients who became MRD-negative immediately after alloHCT. This underlines that durable MRD eradication indeed requires active GvL (as reflected by decreasing MRD load upon immunomodulation), while the predictive value 12-month MRD negativity induced by the conditioning regimen is less robust.
Whenever possible, an MRD-driven stepwise immune modulation algorithm was followed in our patients by deciding about commencement of CNI tapering on the basis of post-transplant MRD kinetics. Although it remains open if this strategy indeed contributed to the relatively low relapse incidence observed in our series, it resulted in a high proportion of patients clearing MRD subsequent to reduction of systemic immunosuppression. Of note, MRD-guided early immunosuppression tapering was not associated with an increased NRM risk.
The interplay between immune modulation, chronic GvHD and MRD kinetics has not been characterized systematically. For the first time, we provide a detailed mapping of the time lag between immune modulation and immune effects, showing that the median time interval from start of CNI tapering and DLI, respectively, to MRD disappearance was relatively long with about 3 months, and in individual patients even considerably longer. This finding is important for designing future immune intervention strategies.
Even though our data suggest that chronic GvHD does not seem to be an absolute prerequisite for GvL efficacy in CLL, the vast majority of patients who showed evidence of immunemediated MRD clearance following CNI reduction or DLI had at least mild-chronic GvHD symptoms, mostly preceding MRD clearance. Albeit the incidence of chronic GvHD cumulated to 61% 1 year after transplant, clinically relevant symptoms were transient in a proportion of patients as indicated by the fact that only 33% of patients at risk required systemic immunosuppression at this landmark. A similar pattern has been reported by investigators from Seattle. 5 Taking into account that active disease at alloHCT may adversely affect relapse risk, 6, 32 we sought to overcome disease resistance at transplant by intensifying conditioning. Indeed in our series the relapse rate after myeloablative conditioning was not higher than after reduced intensity conditioning despite an extremely unfavorable patient selection undergoing myeloablative conditioning, but unfortunately active disease at alloHCT remained associated with a significantly higher NRM risk, resembling findings from the CLL3X study. 9 To this end, the implementation of novel targeting drugs into pre-and posttransplant treatment may be more promising than conditioning intensification for suppressing resistant CLL until GvL activity becomes effective. 30 Information about the outcome of CLL relapse after T-replete alloHCT has been sparse. Our first-line salvage strategy in patients relapsing in the absence of previous GvHD (who represent the vast majority of relapses) was combined immune modulation using DLI and rituximab. Unfortunately this strategy was effective only in a small proportion of patients, even if administered preemptively upon MRD persistence. As lenalidomide had only limited success, most recently we introduced ibrutinib as salvage strategy. In accordance with preliminary observations from the USA, 33 all seven patients rescued with ibrutinib showed clinical response in the absence of adverse reactions within the very limited follow-up time available. Notably, the overall outcome of our patients who had CLL relapse after alloHCT was comparable to that of patients with untransplanted high-risk disease in need for treatment, 34 implying that a previous alloHCT does not necessarily reduce the salvageability of relapsed high-risk CLL. Similarly, investigators from the MD Anderson Cancer Center found that the median OS of 52 patients with untransformed CLL who had relapsed after alloHCT was relatively long with 36 months. 35 Studies addressing further improvement of the overall results of alloHCT in high-risk CLL by implementing novel targeting drugs are warranted. 
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